Galectin Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Galectin Therapeutics's estimated annual revenue is currently $3.5M per year.
- Galectin Therapeutics's estimated revenue per employee is $85,366
- Galectin Therapeutics's total funding is $38.5M.
Employee Data
- Galectin Therapeutics has 41 Employees.
- Galectin Therapeutics grew their employee count by 11% last year.
Galectin Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | CEO and President | Reveal Email/Phone |
5 | VP discovery research/product development | Reveal Email/Phone |
6 | Vice president, commercial development, regulatory affairs and quality assurance | Reveal Email/Phone |
7 | VP, CMC Pharmaceutical Development | Reveal Email/Phone |
8 | VP Clinical Development | Reveal Email/Phone |
9 | Head CMC and Pharmaceutical Development | Reveal Email/Phone |
10 | Director Board Directors | Reveal Email/Phone |
Galectin Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $24.5M | 122 | 8% | N/A | N/A |
#2 | $10.7M | 53 | -17% | N/A | N/A |
#3 | $9.2M | 46 | 2% | N/A | N/A |
#4 | $24.1M | 120 | 5% | N/A | N/A |
#5 | $7.2M | 36 | -20% | N/A | N/A |
#6 | $27.7M | 138 | -30% | N/A | N/A |
#7 | $39.8M | 198 | 37% | N/A | N/A |
#8 | $0.5M | 5 | 25% | $50M | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $10.3M | 51 | 11% | N/A | N/A |
What Is Galectin Therapeutics?
Pro-Pharmaceuticals is a drug development company commercializing a new generation of anti-cancer treatments using carbohydrate molecules to significantly upgrade the safety and efficacy of standard cancer agents. Trading under the symbol PROH.OB, the company is headquartered in Newton, Mass., and was founded in 2000.
keywords:N/A
$38.5M
Total Funding
41
Number of Employees
$3.5M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Galectin Therapeutics News
Galectin Therapeutics (NASDAQ:GALT) Receives New Coverage from Analysts at StockNews.com. Posted by admin on Apr 23rd, 2022.
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3...
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
Other Companies in Norcross
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.3M | 41 | 24% | N/A |
#2 | $6.7M | 41 | 71% | N/A |
#3 | $1.7M | 41 | 3% | N/A |
#4 | $75M | 41 | 5% | N/A |
#5 | $4.9M | 41 | -2% | N/A |